151 related articles for article (PubMed ID: 11284780)
1. Nitrofurantoin quadruple therapy for Helicobacter pylori infection: effect of metronidazole resistance.
Graham DY; Saeed MA; Hoffman J; El-Zimaity HM; Kwon DH; Osato MS
Aliment Pharmacol Ther; 2001 Apr; 15(4):513-8. PubMed ID: 11284780
[TBL] [Abstract][Full Text] [Related]
2. Modified seven-day, quadruple therapy as a first line Helicobacter pylori treatment.
Calvet X; Garcia N; Gené E; Campo R; Brullet E; Sanfeliu I
Aliment Pharmacol Ther; 2001 Jul; 15(7):1061-5. PubMed ID: 11421883
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
Magaret N; Burm M; Faigel D; Kelly C; Peterson W; Fennerty MB
Dig Dis; 2001; 19(2):174-8. PubMed ID: 11549829
[TBL] [Abstract][Full Text] [Related]
4. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.
Miehlke S; Kirsch C; Schneider-Brachert W; Haferland C; Neumeyer M; Bästlein E; Papke J; Jacobs E; Vieth M; Stolte M; Lehn N; Bayerdörffer E
Helicobacter; 2003 Aug; 8(4):310-9. PubMed ID: 12950604
[TBL] [Abstract][Full Text] [Related]
5. Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States.
Graham DY; Belson G; Abudayyeh S; Osato MS; Dore MP; El-Zimaity HM
Dig Liver Dis; 2004 Jun; 36(6):384-7. PubMed ID: 15248377
[TBL] [Abstract][Full Text] [Related]
6. Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study.
Graham DY; Osato MS; Hoffman J; Opekun AR; Anderson SY; Kwon DH; El-Zimaity HM
Aliment Pharmacol Ther; 2000 Jun; 14(6):745-50. PubMed ID: 10848658
[TBL] [Abstract][Full Text] [Related]
7. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
Malfertheiner P; Bazzoli F; Delchier JC; Celiñski K; Giguère M; Rivière M; Mégraud F;
Lancet; 2011 Mar; 377(9769):905-13. PubMed ID: 21345487
[TBL] [Abstract][Full Text] [Related]
8. Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori.
Delchier JC; Malfertheiner P; Thieroff-Ekerdt R
Aliment Pharmacol Ther; 2014 Jul; 40(2):171-7. PubMed ID: 24863854
[TBL] [Abstract][Full Text] [Related]
9. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate.
Fakheri H; Malekzadeh R; Merat S; Khatibian M; Fazel A; Alizadeh BZ; Massarrat S
Aliment Pharmacol Ther; 2001 Mar; 15(3):411-6. PubMed ID: 11207517
[TBL] [Abstract][Full Text] [Related]
10. Randomized study comparing omeprazole with ranitidine as anti-secretory agents combined in quadruple second-line Helicobacter pylori eradication regimens.
Michopoulos S; Tsibouris P; Bouzakis H; Balta A; Vougadiotis J; Broutet N; Kralios N
Aliment Pharmacol Ther; 2000 Jun; 14(6):737-44. PubMed ID: 10848657
[TBL] [Abstract][Full Text] [Related]
11. One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection.
de Boer WA; van Etten RJ; Schade RW; Ouwehand ME; Schneeberger PM; van Unnik AJ; Tytgat GN
Aliment Pharmacol Ther; 1997 Feb; 11(1):109-12. PubMed ID: 9042982
[TBL] [Abstract][Full Text] [Related]
12. [Effectiveness of triple therapy to eradicate H. pylori in patients after failed therapy with omeprazole/amoxicillin].
Zala G; Schwery S; Giezendanner S; Flury R; Wüst J; Meyenberger C; Wirth HP
Schweiz Med Wochenschr; 1996 Feb; 126(5):153-8. PubMed ID: 8685685
[TBL] [Abstract][Full Text] [Related]
13. One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance.
Wong BC; Wong WM; Wang WH; Fung FM; Lai KC; Chu KM; Yuen ST; Leung SY; Hu WH; Yuen MF; Lau GK; Chan CK; Lam SK
Aliment Pharmacol Ther; 2001 Mar; 15(3):403-9. PubMed ID: 11207516
[TBL] [Abstract][Full Text] [Related]
14. Bismuth-based quadruple therapy with bismuth subcitrate, metronidazole, tetracycline and omeprazole in the eradication of Helicobacter pylori.
Lahaie R; Farley A; Dallaire C; Archambault A; Fallone CA; Ponich T; Hunt R; Oravec M; Whitsitt P; Van Zanten SV; Marcon N; Bailey R; Dumont A; Nguyen B; Desrochers S; Spénard J
Can J Gastroenterol; 2001 Sep; 15(9):581-5. PubMed ID: 11573100
[TBL] [Abstract][Full Text] [Related]
15. Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy.
Kung NN; Sung JJ; Yuen NW; Ng PW; Wong KC; Chung EC; Lim BH; Choi CH; Li TH; Ma HC; Kwok SP
Am J Gastroenterol; 1997 Mar; 92(3):438-41. PubMed ID: 9068464
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial.
Salmanroghani H; Mirvakili M; Baghbanian M; Salmanroghani R; Sanati G; Yazdian P
PLoS One; 2018; 13(6):e0197096. PubMed ID: 29889843
[TBL] [Abstract][Full Text] [Related]
17. Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection.
Graham DY; Hoffman J; el-Zimaity HM; Graham DP; Osato M
Aliment Pharmacol Ther; 1997 Oct; 11(5):935-8. PubMed ID: 9354203
[TBL] [Abstract][Full Text] [Related]
18. Omeprazole/amoxicillin versus triple therapy for Helicobacter pylori in duodenal ulcer disease: two-year follow-up of a prospective randomized study.
Labenz J; Stolte M; Peitz U; Tillenburg B; Köhl H; Becker T; Börsch G
Z Gastroenterol; 1995 Oct; 33(10):590-3. PubMed ID: 7502551
[TBL] [Abstract][Full Text] [Related]
19. Inefficacy of triple therapy and comparison of two different bismuth-containing quadruple regimens as a firstline treatment option for helicobacter pylori.
Kekilli M; Onal IK; Ocal S; Dogan Z; Tanoglu A
Saudi J Gastroenterol; 2016; 22(5):366-369. PubMed ID: 27748322
[TBL] [Abstract][Full Text] [Related]
20. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
